AMGEN INC
AMGNNasdaqGSDrug Manufacturers - General • Healthcare
Comprehensive AI Analysis
Strategic AI Analysis for AMGN
Checking whether the approved providers contain enough current financial data for a reliable report.
Summary
Source-linked company research for AMGN
Factor Scorecard
Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.
Latest results at a glance
Insights from the latest company results and reports
Quarterly Earnings Exceed Consensus
Reported EPS of $6.29 per share exceeded the same-quarter consensus estimate of $5.62 for the period ended 2026-06-30.
Revenue Growth Accelerates
Revenue for the quarter ended 2026-06-30 was $10.05bn, up 9.53% from $9.18bn in the same quarter of the prior year.
Net Income Rises Sharply
Net income for the quarter ended 2026-06-30 was $2.38bn, up 65.85% from $1.43bn in the comparable prior-year quarter.
Gross Margin Expands
Gross margin for the quarter ended 2026-06-30 was 72.04%, wider than the 67.20% recorded for the quarter ended 2025-06-30.
Other Products Segment Grows
Other Products revenue of $5.44bn was 14.8% of consolidated revenue for the period ended 2025-12-31, up 34.7% from $4.04bn in 2024-12-31.
Phase 3 Trial Success
[2026-08-27] AstraZeneca and Amgen reported that Tezspire met co-primary and key secondary endpoints in the Phase 3 CROSSING trial for eosinophilic esophagitis.
Price Chart
NASDAQ:AMGN via TradingView
Loading TradingView chart...
Overview
Quarterly income statement data isn't available for this company.
No Data
No annual financial data available.
Financial Fundamentals
Growth, quality, valuation, cash generation, and balance-sheet strength.
Growth
TTM revenue plus current, long-term, forward, and accelerating top-line trends.
Earnings
Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.
Profitability
TTM margin and return metrics that reflect pricing power and business quality.
Cash Flow
TTM free cash flow, growth, margin, and operating-cash conversion quality.
Valuation
Metrics ranked by issuer type, financial state, and input quality.
Forward P/E
Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.
Financial Health
Latest-quarter liquidity and leverage checks plus TTM interest coverage.
Shareholder Signals
Capital returns and dilution checks sourced from statements and insider filings.
Peer Comparison
| Ticker | Price | Mkt Cap | EV/EBITDA | Fwd P/E | Rev Growth | Gross Margin | FCF Yield |
|---|---|---|---|---|---|---|---|
AMGNAMGEN INC | $432.42 | $233.8B | 22.5x | 18.8x | +9.1% | 69.5% | 4.4% |
Company Profile
About the Company
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Next Earnings Date
Nov 3, 2026
Loading latest news...